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Discussion of controversies in the
measurement of nitric oxide metabolites
in biological matrices
Santiago Lamas (Associate Editor)
We incorporate a new section in Redox Biology, the Editors'
forum. The main objective is to attract short contributions related
to previously published articles that may help to clarify concepts,
open controversies or constructively criticize conclusions from a
speciﬁc article. The contribution will show a link to the related
article and may be accompanied by the appropriate response of
the authors to the commentary on their article.
The article by Drs. Cortese-Krott and Kelm [1] promoted an
extensive analysis by Dr. Tsikas about the optimal methodology to
characterize eNOS activity in red blood cells and its relevance
for the concepts put forward by Cortese-Krott and Kelm. The
authors were given the opportunity to respond to this commen-
tary and their answer is shown below the commentary. Indeed
this is an important question as the jury appears to be still out
concerning the existence of a NOS isoform in human red blood
cells. Dr. Tsikas makes a strong case on the validity of the gas
chromatography-mass spectrometry (GC-MS) NOS activity assay
for a large set of samples, including erythrocytes, and delves into
the complex chemistry involved. Drs. Cortese-Krott and Kelm
lucidly respond to Dr. Tsikas with equally powerful arguments.
We are proud to host this illuminating discussion on a complex
chemical topic and we invite all readers to follow this example and
submit commentaries that may contribute to enhance progress in
the understanding of challenging notions in the ﬁeld of redox
biology.
http://dx.doi.org/10.1016/j.redox.2015.01.018
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To the Editor
I read with interest the article by Cortese-Krott and Kelm [1]
who reviewed and discussed the at ﬁrst glance paradoxical, yet
potentially important and formidably challenging issue of nitric
oxide (NO) synthesis from L-arginine by endothelial NO synthase
(eNOS) in red blood cells (RBCs), a possibly new erythrocrine
function. In consideration of the high concentration of hemoglobin
in erythrocytes (about 10 mM) and the high afﬁnity of O2, NO and
carbon monoxide (CO) and presumably of other gases to the heme
group of hemoglobin, the majority of scientists believes that RBCs
behave toward NO as do super-massive black holes behave against
matter and even light, with other words as “NO sinks”. Yet, in
practice we see that RBCs are able to export NO and other NO
species that can ﬁnally exert cGMP-dependent and cGMP-
independent NO-related activities in the circulation. With respect
to this issue I fully agree with the statements, arguments and
conclusions by Cortese-Krott and Kelm in their review article [1].
However, I do not agree with the authors on their argument
concerning the alleged chemistry of NOS-derived NO in RBCs and
that this particular NO chemistry may explain our failure to
measure NOS activity in human RBCs by means of a previously
reported, fully-validated [2] and cross-validated [3] gas chromato-
graphy–mass spectrometry (GC–MS) NOS activity assay.
The principle of our GC–MS NOS activity assay [2] used in vivo
and in vitro in blood cells including human RBCs [4] and platelets
[3,5] and the major reactions of NO and its major metabolites/
reaction products, nitrate and nitrite, are illustrated in Fig. 1. We
use L-[guanidino-15N2]-arginine as the substrate for NOS which
oxidizes one of the two 15N-labeled atoms of L-[guanidino-15N2]-
arginine to 15NO, with L-[ureido-15N]-citrulline being the second
reaction product. Because authentic 15NO is not detectable at low
NOS activity values as in the case of endothelial NOS (eNOS),
analytically accessible metabolites/reaction products of 15NO are
analyzed instead. It must be emphasized that all eNOS activity
assays are exclusively based on the measurement of NO metabo-
lites/reaction products because of the pretty low NO formation
rate. In aqueous solutions including blood 15NO is autoxidized to
15N-nitrite (15NO2), albeit to a minor extent [6]. NOS isozymes are
able to oxidize its own 15NO to 15N-nitrate (O15NO2) [3]. In
aqueous solutions of recombinant eNOS solutions and in washed
human platelets suspensions, the 15NO2-to-O15NO2 molar ratio is
about 1:1 [5]. In human erythrocytes suspensions in regular
buffers of neutral pH value or in whole blood [6], 15NO-derived
15NO2 is practically undetectable, because 15NO is rapidly oxidized
by oxyhemoglobin (HbFeIIO2) to O15NO2 . Thus, in RBCs eNOS
would convert L-[guanidino-15N2]-arginine to 15NO which would
be oxidized to O15NO2 largely by HbFeIIO2 and to a minor extent
by eNOS (Fig. 1). In theory, a very small fraction of L-[guanidi-
no-15N2]-arginine/eNOS-derived 15NO would autoxidize to 15NO2
which would almost uniformly partition between plasma and
RBCs. Erythrocytic 15NO2 would ﬁnally be oxidized to O15NO2
by HbFeIIO2. This is supported by our observation that synthetic
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15NO gas is oxidized in human whole blood to O15NO2 and 15NO2
with a molar ratio of about 250:1 after 15 min of continuous 15NO
bubbling at 25 1C [6]. As rightly discussed by Cortese-Krott and
Kelm [1], NO in general and 15NO in case of using L-[guanidi-
no-15N2]-arginine as well as unlabeled nitrite (i.e., 14NO2) and
15NO2 would undergo additional, yet less abundant reactions with
hemoglobin species and presumably with other erythrocytic
biomolecules including enzymes such as xanthine-
oxidoreductase (XOR) and carbonic anhydrase (CA) (Fig. 1).
Because nitrate is by far the most abundant NO metabolite in
human RBCs [6–8], there is no doubt that measurement of O15NO2
in lyzed RBCs will ultimately reﬂect NOS activity. As soon as 15NO
is formed from eNOS-catalyzed oxidation of L-[guanidino-15N2]-
arginine externally added to RBCs, the subsequent reactions will
not compromise at all the assessment of eNOS activity by measur-
ing O15NO2 by our GC–MS method. Under the conditions we used
to measure NOS activity in RBCs, we measured a half-life of about
12 min for 15NO2 , which, moreover, is almost entirely oxidized to
O15NO2 [6]. To the best of my knowledge, there is no single
published study to report on complete reduction of nitrate, nitrite
or S-nitrosothiols to NO in RBCs, for instance by XOR, CA,
methemoglobin or ceruloplasmin, at least in freshly obtained
and used human RBCs. Therefore, the statement by Cortese-Krott
and Kelm [1] “Measuring changes in 15N/14N-nitrite or 15N/14N-
nitrate ratios after incubation with 15N L-arginine [71] in the
presence of high concentrations of hemoglobin may not necessa-
rily reﬂect true NOS activity because the chemistry of formation of
nitrite and nitrate from NO may be dependent on other competing
reactions involving NO/NO metabolites and oxy/deoxy/methemo-
globin (metHb, FeIIIHb) occurring, which could conceivably affect
not only NO but also nitrite and nitrate levels. These considera-
tions include, but are not limited to the oxyHb-dependent con-
versions of NO and nitrite to nitrate [42], the presence of
ceruloplasmin [73] and/or other plasma proteins converting NO
into nitrite, and the enzymatic conversion of nitrite back to NO (for
example catalyzed by XOR [43])” is not supported by any experi-
mental data. In this context, we should also not disregard the
several orders of magnitude molar excess of hemoglobin over
diaminoﬂuorescein (DAF) reagents. With respect to our fully-
validated GC–MS NOS activity assay [2], which is both speciﬁc
and sensitive and works equally well in numerous complex
biological matrixes, including plasma, serum, whole blood, ery-
throcytes, saliva, urine, tissues (liver, kidney, stomach, lung, brain),
and various cells [2–6,9–11], the failure to measure NOS activity in
RBCs [4] and platelets [5] of healthy subjects under regular
experimental conditions is not an analytical issue. With regard
both to human RBCs and human platelets, our studies indicate that
these cell types lack NOS activity.
As to human blood platelets, there is convincing evidence by a
proteomics-based study that these cells do not express any NOS
proteins [12]. Detection of NOS proteins in human blood platelets
by many other groups are likely to be due to the use of unspeciﬁc
NOS antibodies [13]. It is generally accepted for many years that
(human) blood platelets express functional NOS. However, not
only recently reported studies but also studies reported 25 years
ago, for instance by the group of Vane [14], suggest that human
platelets lack NOS activity and that measurement of NOS activity
in platelets preparations are likely to be artefactual due to
contaminating neutrophils and mononuclear cells [14].
Kelm and his scientiﬁc partners are long-standing leaders in
the area of NO research and have contributed signiﬁcant work
including the development of sophisticated analytical methods
and clinical protocols to study the pathophysiology of NO in the
human vasculature. Kelm and colleagues reported both on the
expression and the functionality of eNOS in RBCs of healthy and
sick subjects [15,16]. As our group did not investigate the occur-
rence of NOS proteins in human RBCs, we cannot comment on the
presence or absence of NOS proteins in human RBCs (and human
blood platelets). Yet, the discrepancy concerning the functionality
of NOS in human RBCs between our groups remains unresolved at
present. Even if NOS would be present and active in RBCs, its
activity would be very low. I am convinced that the most reliable
way to assess NOS activity is the use of L-[guanidino-15N2]-arginine
and the measurement of analytically easily accessible 15NO meta-
bolites, i.e., O15NO2 (and perhaps 15NO2) in RBCs. Measurement of
unlabeled nitrite (i.e., 14NO2) and/or nitrate (i.e., O14NO2) always
bears the risk of detecting nitrite and/or nitrate not deriving from
the L-arginine/NOS system in RBCs during the performance of the
NOS assay. Besides XOR, CA isozymes, which are abundantly
present in RBCs, may also artefactually contribute to NO unrelated
to the L-arginine/NOS pathway [17–19]. Measurement of unla-
beled, stable-isotope labeled [3] and/or radio-labeled citrulline
Fig. 1. Schematic of the GC-MS-based NOS activity assay [2] adopted for the measurement of NOS activity in RBCs [4]. The externally added substrate L-[guanidino-15N2]-
arginine is transported inside the RBCs. Functional NOS would convert L-[guanidino-15N2]-arginine to L-[ureido-15N]-citrulline and 15NO. A small portion of 15NO would
autoxidize to 15N-nitrite (15NO2) and in part be oxidized to 15N-nitrate (O15NO2) by NOS itself. The major fraction of 15NO would be oxidized to O15NO2 by oxyhemoglobin.
15NO-derived 15NO2 would also be oxidized to O15NO2 by oxyhemoglobin. In addition to these reactions, 15NO and 15NO-derived 15NO2 may undergo further, yet much less
abundant reactions. However, the ﬁnal and most abundant L-[guanidino-15N2]-arginine/15NO-derived metabolite would be O15NO2 . 15NO2 and O15NO2 are simultaneously
derivatized with pentaﬂuorobenzyl bromide and then simultaneously analyzed by GC-MS (not shown); the detected ions are 15NO2 and O15NO2 [2, 4]. Hb, hemoglobin;
XOR, xanthine-oxidoreductase; CA, carbonic anhydrase. The width of the arrows is only an approximate indicator of the contribution of the respective reactions.
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produced from the respective L-arginine species by enzymes-
involving pathways distinctly different from L-arginine/NOS also
bears the risk of detecting artefactually NOS activity.
Speciﬁc detection of NOS proteins and unequivocal measure-
ment of their activity in blood cells are big analytical challenges.
Our knowledge about NO chemistry, biochemistry and pathophy-
siology grew enormously in the past decades. The unimaginable
complexity of the cellular biology bears a high risk of generating
inaccurate analytical results and of drawing uncertain conclusions.
By nature, RBCs represent an especially difﬁcult terrain to NO
researchers interested in expression and functionality of erythro-
cytic NOS, like the black holes to astronomers. The enigma and the
paradox of expression and functionality of NOS in RBCs remain to
be elucidated. Mass spectrometry is the key analytical tool in this
endeavor.
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Response to commentary
Miriam M. Cortese-Krott, Malte Kelm
In our article [1] we discussed the history of detection,
unequivocal identiﬁcation by enzymatic and analytical techniques
including electrospray ionization tandem mass spectrometry (ESI–
MS/MS), and potential pathophysiological signiﬁcance of red cell
eNOS, i.e. nitric oxide synthase isoform 3, or "endothelial" isoform
carried by red blood cells (RBCs), and put forward the hypothesis
that red cell eNOS may play a role in the signaling and function of
RBCs and possibly cardiovascular pathophysiology.
As pointed out by Dr. Tsikas in his current letter to the Editor of
Redox Biology, his group never investigated the occurrence of
NOS/eNOS protein in RBC; rather, he reported on the capacity of
RBC suspensions or lysates to convert L-15N-arginine into 15N-
nitrate. These results were published in a Letter to Blood in May
2012 [2], which to the best of our knowledge is the only publica-
tion to date that presented data related to the enzymatic conver-
sion of L-15N-arginine to 15N-nitrate in RBC. Those results show
that (A) suspensions of RBC (from 1 blood donor) take up 15N
arginine in the presence and absence of glucose (Fig. 1A); (B) the
ratios of 15N/14N-nitrite and 15N/14N-nitrate, in an RBC suspension
(from 1 blood donor), do not differ at all (nitrite) or increase only
marginally (nitrate) when cells were incubated with 0.4 mM
L-15N-arg at 37 1C for 20 min (Fig. 1B); (C) addition of 5 mM
L-15N-arg to RBC lysates (from EDTA blood of 5 donors) – the
ratio of 15N/14N nitrate did not change with time (Fig. 1C) whereas
the ratio changed from 0.008 to 0.012 after addition of 50 mg/ml
recombinant human eNOS (Fig. 1C).
Thus, these results seem to demonstrate that addition of 15N-L-
arginine does not affect the 15N/14N-nitrate ratio, and that even the
addition of excess recombinant eNOS increases these ratios only by
1.5 fold, failing to increase further with time. Considering that the
commercial recombinant eNOS enzyme preparation used has an
activity of at least 125 U/mg (http://www.enzolifesciences.com/
ALX-201-853/enos-human-recombinant/), and that the amount of
enzyme added was 50 mg/ml, this should have resulted in a speciﬁc
activity of at least 6.25 nmoles NO/ml/min or an NO yield of
187.5 nmoles/ml (i.e. mM) over a 30 min incubation period. It is
surprising that the addition of such signiﬁcant amounts of recombi-
nant eNOS to RBC lysates increased the 15N/14N-nitrate ratio only
1.5 fold, and failed to increase this ratio beyond 20 min of incuba-
tion. Thus, either NOS cofactors were severely limited and/or the
method of detection of the NOS products was not very sensitive in
this matrix. Now considering that in our and other investigators'
hands both the amount of protein, and its activity is low (e.g. [1,3–9],
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